In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guerlain retires

This article was originally published in The Rose Sheet

Executive Summary

Master perfumer Jean-Paul Guerlain has retired as head of the Parisian fragrance house after 47 years, LVMH announces. Guerlain will focus on writing his memoirs, which are expected to be published in October. Fifth-generation perfumer assumed the helm of the 174-year-old company in 1959. During his tenure, Guerlain was instrumental in bringing to market more than 60 fragrances including Vetiver (1959), Nahema (1979), Samsara (1989), Héritage (1992) and his most personal offering, Mahora (2001). Creation of Mahora was designed as a testament to beautiful, sexy women of all ages (11"The Rose Sheet" Nov. 20, 2000, p. 5). Guerlain's retirement follows the resignation of U.S. President and CEO Marjorie Wollan (22"The Rose Sheet" Nov. 5, 2001, p. 8)...

You may also be interested in...



Guerlain Mahora Fragrance Blossoms Under $2 Mil.-$3 Mil. Ad Campaign

Perfumer Jean-Paul Guerlain's latest and most modern fragrance, Mahora, will bow stateside in April backed by a $2 mil.-$3 mil. ad spend, the LVMH company said at a press event in New York City Nov. 15.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.

UsernamePublicRestriction

Register

RS009961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel